aviarapharma.com valuation and analysis
Robots.txt Information
| Robot | Path | Permission |
| GoogleBot | / | ✔ |
| BingBot | / | ✔ |
| BaiduSpider | / | ✔ |
| YandexBot | / | ✔ |
User-agent: * | ||
Meta Tags
| Title | Aviara |
| Description | Aviara is leading the development of small molecule integrin inhibitors that modulate the activity of stem cells and inflammatory cells. Aviara’s lead cli |
| Keywords | N/A |
Server Information
| WebSite | |
| Host IP | 209.17.116.9 |
| Location | United States |
Related Websites
| Site | Rank |
More to Explore
aviarapharma.com Valuation
|
US$1,423,109
Last updated: 2023-05-12 12:43:06
aviarapharma.com has Semrush global rank of 7,437,451. aviarapharma.com has an estimated worth of US$ 1,423,109, based on its estimated Ads revenue. aviarapharma.com receives approximately 164,205 unique visitors each day. Its web server is located in United States, with IP address 209.17.116.9. According to SiteAdvisor, aviarapharma.com is safe to visit. |
Traffic & Worth Estimates
| Purchase/Sale Value | US$1,423,109 |
| Daily Ads Revenue | US$1,314 |
| Monthly Ads Revenue | US$39,410 |
| Yearly Ads Revenue | US$472,911 |
| Daily Unique Visitors | 10,947 |
| Note: All traffic and earnings values are estimates. | |
DNS Records
| Host | Type | TTL | Data |
| aviarapharma.com. | A | 7199 | IP: 209.17.116.9 |
| aviarapharma.com. | NS | 7200 | NS Record: ns71.worldnic.com. |
| aviarapharma.com. | NS | 7200 | NS Record: ns72.worldnic.com. |
| aviarapharma.com. | MX | 7200 | MX Record: 10 aviarapharma-com.mail.protection.outlook.com. |
| aviarapharma.com. | TXT | 7200 | TXT Record: v=spf1 include:spf.protection.outlook.com -all |
| aviarapharma.com. | TXT | 3600 | TXT Record: MS=ms13953824 |
HtmlToTextCheckTime:2023-05-12 12:43:06
| Aviara is leading the development of small molecule integrin inhibitors that modulate the activity of stem cells and inflammatory cells. Aviara’s lead clinical candidate, AVA4746, is being developed for the mobilization of hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with leukemia or lymphoma. In addition to AVA4746, Aviara is also developing a portfolio of small-molecule antagonists against a variety of integrin targets involved in the modulation of cell therapies and inflammatory disease such as minimal residual disease in cancer, cardiac stem cell transplant, dry eye disease and inflammatory bowel disease. Aviara has a collaboration with the Texas Heart Institute (THI) to explore the roles of integrins and other adhesion molecules in the development and trafficking of stem cells. Aviara and THI have entered into a joint discovery, development and cross-license agreement that provides access to THI research for |
HTTP Headers
HTTP/1.1 200 OK Content-Length: 19617 Content-Type: text/html Last-Modified: Thu, 12 Nov 2020 01:38:10 GMT Accept-Ranges: bytes ETag: "62ce757a94b8d61:0" Server: Microsoft-IIS/10.0 X-Powered-By: ASP.NET X-Powered-By: ARR/3.0 Date: Fri, 17 Dec 2021 08:44:43 GMT |
aviarapharma.com Whois Information
Domain Name: AVIARAPHARMA.COM Registry Domain ID: 1570809519_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.networksolutions.com Registrar URL: http://networksolutions.com Updated Date: 2021-08-01T08:30:18Z Creation Date: 2009-09-30T16:24:57Z Registry Expiry Date: 2022-09-30T16:24:57Z Registrar: Network Solutions, LLC Registrar IANA ID: 2 Registrar Abuse Contact Email: abuse@web.com Registrar Abuse Contact Phone: +1.8003337680 Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Name Server: NS71.WORLDNIC.COM Name Server: NS72.WORLDNIC.COM DNSSEC: unsigned >>> Last update of whois database: 2021-12-17T07:27:02Z <<< |